CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

NCT07077083 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC)
ccRCC

Interventions

DRUG: 89Zr-Girentuximab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]